TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis
- Author:
Kyungsoo JUNG
1
;
Joon-Seok CHOI
;
Beom-Mo KOO
;
Yu Jin KIM
;
Ji-Young SONG
;
Minjung SUNG
;
Eun Sol CHANG
;
Ka-Won NOH
;
Sungbin AN
;
Mi-Sook LEE
;
Kyoung SONG
;
Hannah LEE
;
Ryong Nam KIM
;
Young Kee SHIN
;
Doo-Yi OH
;
Yoon-La CHOI
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2021;53(1):9-24
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:To find biomarkers for disease, there have been constant attempts to investigate the genes that differ from those in the disease groups. However, the values that lie outside the overall pattern of a distribution, the outliers, are frequently excluded in traditional analytical methods as they are considered to be ‘some sort of problem.’ Such outliers may have a biologic role in the disease group. Thus, this study explored new biomarker using outlier analysis, and verified the suitability of therapeutic potential of two genes (TM4SF4 and LRRK2).
Materials and Methods:Modified Tukey’s fences outlier analysis was carried out to identify new biomarkers using the public gene expression datasets. And we verified the presence of the selected biomarkers in other clinical samples via customized gene expression panels and tissue microarrays. Moreover, a siRNA-based knockdown test was performed to evaluate the impact of the biomarkers on oncogenic phenotypes.
Results:TM4SF4 in lung cancer and LRRK2 in breast cancer were chosen as candidates among the genes derived from the analysis. TM4SF4 and LRRK2 were overexpressed in the small number of samples with lung cancer (4.20%) and breast cancer (2.42%), respectively. Knockdown of TM4SF4 and LRRK2 suppressed the growth of lung and breast cancer cell lines. The LRRK2 overexpressing cell lines were more sensitive to LRRK2-IN-1 than the LRRK2 under-expressing cell lines
Conclusion:Our modified outlier-based analysis method has proved to rescue biomarkers previously missed or unnoticed by traditional analysis showing TM4SF4 and LRRK2 are novel target candidates for lung and breast cancer, respectively.
